Banque Pictet & Cie SA bought a new position in Sanofi (NYSE:SNY) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 4,680 shares of the company’s stock, valued at approximately $465,000.
Several other hedge funds also recently added to or reduced their stakes in the company. Moors & Cabot Inc. raised its stake in Sanofi by 0.7% during the second quarter. Moors & Cabot Inc. now owns 6,494 shares of the company’s stock valued at $311,000 after purchasing an additional 43 shares in the last quarter. Strategic Global Advisors LLC raised its stake in shares of Sanofi by 0.6% in the second quarter. Strategic Global Advisors LLC now owns 8,632 shares of the company’s stock valued at $414,000 after acquiring an additional 54 shares during the period. First City Capital Management Inc. raised its stake in shares of Sanofi by 0.3% in the second quarter. First City Capital Management Inc. now owns 38,389 shares of the company’s stock valued at $1,839,000 after acquiring an additional 100 shares during the period. Synovus Financial Corp raised its stake in shares of Sanofi by 2.7% in the second quarter. Synovus Financial Corp now owns 4,621 shares of the company’s stock valued at $219,000 after acquiring an additional 122 shares during the period. Finally, Toronto Dominion Bank raised its stake in shares of Sanofi by 4.6% in the second quarter. Toronto Dominion Bank now owns 4,054 shares of the company’s stock valued at $195,000 after acquiring an additional 180 shares during the period. 9.09% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts have recently weighed in on the stock. J P Morgan Chase & Co reissued a “neutral” rating on shares of Sanofi in a research note on Friday, September 15th. Morgan Stanley cut shares of Sanofi from an “overweight” rating to an “underweight” rating in a report on Friday. Barclays upgraded shares of Sanofi from an “underweight” rating to an “equal weight” rating in a report on Wednesday, November 15th. upgraded shares of Sanofi from a “reduce” rating to a “hold” rating in a report on Wednesday, August 30th. Finally, Zacks Investment Research cut shares of Sanofi from a “hold” rating to a “strong sell” rating in a report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $53.50.
Sanofi (NYSE SNY) traded down $0.46 during trading hours on Monday, hitting $44.16. 1,538,472 shares of the stock were exchanged, compared to its average volume of 1,504,267. Sanofi has a twelve month low of $38.45 and a twelve month high of $50.65. The company has a market cap of $112,509.69, a PE ratio of 14.08, a P/E/G ratio of 2.46 and a beta of 0.86. The company has a quick ratio of 1.16, a current ratio of 1.59 and a debt-to-equity ratio of 0.26.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/04/banque-pictet-cie-sa-takes-position-in-sanofi-sny.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.